Last reviewed · How we verify
NCT06108453
A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Methotrexate in Elderly Subjects
Phase 1 trial testing Methotrexate Sodium in Drug Interactions in 10 participants. Status unknown.
24 October 2024
Quick facts
| Lead sponsor | Seoul National University Bundang Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 10 |
| Start date | 21 August 2023 |
| Primary completion | 24 October 2024 |
| Estimated completion | 24 November 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Methotrexate Sodium — full drug profile →
- Rifampicin (Rifampicin) — full drug profile →
Conditions studied
- Drug Interactions — all drugs for Drug Interactions →
Sponsor
Seoul National University Bundang Hospital
Who can join
Adults 70 to 80, any sex, with Drug Interactions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To investigate the effect of rifampicin on the pharmacokinetics of methotrexate.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06108453
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Methotrexate Sodium
Trials testing the same drug.
- NCT06354439 — Use of Letrozole for Ectopic Pregnancy · Phase 4 · recruiting
- NCT05575297 — A Drug-drug Interaction Study to Evaluate the Effect of Rifampicin and Febuxostat on the Pharmacokinetics of Methotrexat · Phase 1 · completed
- NCT02143414 — Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acu · Phase 2 · active not recruiting
Other recruiting trials for Drug Interactions
Currently open trials in the same condition.
- NCT06865885 — LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering · Phase 4 · recruiting
- NCT06757140 — Opioid Drug Interaction Study · Phase 1, PHASE2 · recruiting
- NCT06401863 — Shared Decision for Drug Interactions in Oral Anticoagulation · NA · recruiting
- NCT06159699 — Telecommunication Technology-based Online Survey · recruiting
Other Seoul National University Bundang Hospital trials
Trials by the same sponsor.
- NCT07459725 — Comparison of EEG-Timed vs. Repetitive Robot Therapy for Chronic Stroke · NA · not yet recruiting
- NCT07455279 — Surface Electromyographic Analysis of Normal Swallowing in Children: An Exploratory Study · not yet recruiting
- NCT07477574 — Muscle-Specific Multimodal AI for Sarcopenia Diagnosis · NA · not yet recruiting
- NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
- NCT07305662 — Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGU · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06108453 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Seoul National University Bundang Hospital
- Last refreshed: 31 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06108453.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing